Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
26 Junio 2023 - 7:03AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
under
the Securities Exchange Act of 1934
For
the month of: June 2023
Commission
file number: 001-36578
ENLIVEX
THERAPEUTICS LTD.
(Translation
of registrant’s name into English)
14
Einstein Street, Nes Ziona, Israel 7403618
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
On
June 26, 2023, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), issued
a press release announcing its financial results for the first quarter ended March 31, 2023 and the prior filing on June 16, 2023 with
the Securities and Exchange Commission of the Company’s unaudited condensed consolidated financial statements, as of and for the
three month periods ended March 31, 2023 and 2022 and related management’s discussion for such periods. A copy of such press release
is furnished as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
Enlivex
Therapeutics Ltd. |
| |
(Registrant) |
| |
|
| |
By: |
/s/
Oren Hershkovitz |
| |
Name:
Title: |
Oren
Hershkovitz
Chief Executive Officer |
Date:
June 26, 2023
Enlivex Therapeutics (NASDAQ:ENLV)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
